NCT00950989 - Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate | Biotech Hunter

Enrollment

252

Participants

Timeline

Start Date

December 30, 2009

Primary Completion Date

February 11, 2011

Study Completion Date

February 11, 2011

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Brodalumab

3 single subcutaneous (SC) injections at day 1 and weeks 1, 2, 4, 6, 8, and 10

DRUG

Placebo

3 single SC injections at day 1 and weeks 1, 2, 4, 6, 8, and 10

DRUG

Methotrexate

Two methotrexate dose adjustments were allowed in the event of methotrexate toxicity, however, doses \< 7.5 mg/week necessitated discontinuation from study.

DIETARY_SUPPLEMENT

folic acid

at least 5 mg per week